DrugPatentWatch Database Preview
Details for Patent: 10,406,199
» See Plans and Pricing
Which drugs does patent 10,406,199 protect, and when does it expire?
Patent 10,406,199 protects QBRELIS and is included in one NDA.
This patent has seven patent family members in seven countries.
Summary for Patent: 10,406,199
| Title: | Lisinopril formulations |
| Abstract: | Provided herein are stable lisinopril oral liquid formulations. Also provided herein are methods of using lisinopril oral liquid formulations for the treatment of certain diseases including hypertension, heart failure and acute myocardial infarction. |
| Inventor(s): | Mosher; Gerold L. (Kansas City, MO), Miles; David W. (Kansas City, MO) |
| Assignee: | SILVERGATE PHARMACEUTICALS, INC. (Greenwood Village, CO) |
| Application Number: | 16/295,482 |
|
Patent Claim Types: see list of patent claims | Use; Formulation; |
Drugs Protected by US Patent 10,406,199
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF MYOCARDIAL INFARCTION | Start Trial | ||||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | METHOD OF TREATING HYPERTENSION | Start Trial | ||||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF HEART FAILURE | Start Trial | ||||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | METHOD OF TREATMENT OF HEART FAILURE | Start Trial | ||||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | REDUCTION OF MORTALITY IN ACUTE MYOCARDIAL INFARCTION | Start Trial | ||||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | TREATMENT OF HYPERTENSION | Start Trial | ||||
| Azurity | QBRELIS | lisinopril | SOLUTION;ORAL | 208401-001 | Jul 29, 2016 | RX | Yes | Yes | Start Trial | Start Trial | ACUTE MYOCARDIAL INFARCTION | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,406,199
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Canada | 3003274 | Start Trial | |||
| China | 108472252 | Start Trial | |||
| European Patent Office | 3368012 | Start Trial | |||
| Hong Kong | 1258803 | Start Trial | |||
| Japan | 2018533583 | Start Trial | |||
| South Korea | 20180069907 | Start Trial | |||
| World Intellectual Property Organization (WIPO) | 2017075368 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
